Research ArticleArticle
Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation
Minako Sugiyama, Ken-ichi Fujita, Norie Murayama, Yuko Akiyama, Hiroshi Yamazaki and Yasutsuna Sasaki
Drug Metabolism and Disposition May 2011, 39 (5) 757-762; DOI: https://doi.org/10.1124/dmd.110.037853